A Phase 3 Trial of MM120 for Generalized Anxiety Disorder

Description

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama

Conditions

Generalized Anxiety Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder

Condition
Generalized Anxiety Disorder
Intervention / Treatment

-

Contacts and Locations

Little Rock

Preferred Research Partners, Inc., Little Rock, Arkansas, United States, 72211

Los Angeles

West Los Angeles VA Medical Center, Los Angeles, California, United States, 90073

Torrance

Cenexel-CNS, Torrance, California, United States, 90504

Bradenton

Bradenton Research Center, Inc., Bradenton, Florida, United States, 34205

Orlando

Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States, 32801

Atlanta

Atlanta Center for Medical Research, Atlanta, Georgia, United States, 30331

Towson

Sheppard Pratt Health System, Towson, Maryland, United States, 21204

Boston

Copley Clinical, Boston, Massachusetts, United States, 02116

Princeton

Princeton Medical Institute, Princeton, New Jersey, United States, 08540

Cincinnati

University of Cincinnati Psychiatry- Anxiety Disorders Research Program, Cincinnati, Ohio, United States, 45219

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male or female: must be between 18 (or the legal age of consent in the jurisdiction in which the study is taking place) and 74 years of age inclusive, at the time of signing the informed consent.
  • 2. Diagnosis of GAD per DSM-5
  • 3. HAM-A Total Score ≥20
  • 1. Any psychiatric disorder (other than generalized anxiety disorder)
  • 2. First degree relative with or lifetime history of a psychotic disorder.
  • 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine).
  • 4. Any clinically significant unstable illness.

Ages Eligible for Study

18 Years to 74 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mind Medicine, Inc.,

Study Record Dates

2027-05-04